<DOC>
	<DOC>NCT02150343</DOC>
	<brief_summary>The purpose of this study is to compare the treatment effect of three treatment regimens of HDM-SPIRE vs placebo and to evaluates the treatment effect of HDM-SPIRE on symptoms, rescue medication usage, Quality of Life and Sleep Quality</brief_summary>
	<brief_title>Phase II HDM-SPIRE Safety and Efficacy Study</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Male or female, aged 1865 years. Moderate to severe rhinoconjunctivitis on exposure to HDM for at least 1 years. Mean TRSS ≥10 Positive skin prick test to Der p and Der f. Dep p and Der f specific IgE ≥0.7 kU/L Diagnosis of asthma requiringGlobal Initiative for Asthma (GINA) Step 3 (www.ginasthma.org)or higher treatment FEV1 &lt;80% of predicted. Clinically significant confounding symptoms of allergy to seasonal allergens during the final evaluation period. Significant symptoms of another clinically relevant illness that is likely to affect scoring of rhinoconjunctivitis symptoms. Clinically relevant abnormalities detected on physical examination. History of severe drug allergy, severe angioedema or anaphylactic reaction to food.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Cat allergy</keyword>
	<keyword>Rhinoconjunctivitis</keyword>
</DOC>